WO2018001944A1

WO2018001944A1 - Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Info

Publication number: WO2018001944A1
Application number: PCT/EP2017/065672
Authority: WO
Inventors: Zhanling CHENG; Xingchun Han; Min Jiang; Song Yang
Original assignee: F. Hoffmann-La Roche Ag; Hoffmann-La Roche Inc.
Priority date: 2016-06-29
Filing date: 2017-06-26
Publication date: 2018-01-04
Also published as: US20190241570A1; JP2019519590A; US11225482B2; CN109415367A; CN109415367B; EP3478686A1; EP3478686B1; JP6821716B2

Abstract

The present invention provides novel compounds having the general formula: wherein R¹, R², A and X are as described herein, compositions including the compounds and methods of using the compounds.

Description

Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection

The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to HBsAg (HBV Surface antigen) inhibitors and HBV DNA production inhibitors useful for treating HBV infection.

FIELD OF THE INVENTION The present invention relates to novel dihydropyrrolopyrimidines having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.

The present invention relates to compounds of formula I

wherein R¹ , R², A and X are as described below, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

The hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus. The compact 3.2 kb HBV genome consists of four overlapping open reading frames (ORF), which encode for the core, polymerase (Pol), envelope and X-proteins. The Pol ORF is the longest and the envelope ORF is located within it, while the X and core ORFs overlap with the Pol ORF. The lifecycle of HBV has two main events: 1) generation of closed circular DNA (cccDNA) from relaxed circular (RC DNA), and 2) reverse transcription of pregenomic RNA (pgRNA) to produce RC DNA. Prior to the infection of host cells, the HBV genome exists within the virion as RC DNA. It has been determined that HBV virions are able to gain entry into host cells by non-specifically binding to the negatively charged proteoglycans present on the surface of human hepatocytes (Schulze, A., P. Gripon & S. Urban. Hepatology, 46, (2007), 1759-68) and via the specific binding of HBV surface antigens (HBsAg) to the hepatocyte sodium- taurocholate cotransporting polypeptide (NTCP) receptor (Yan, H. et al. J Virol, 87, (2013), 7977-91). Once the virion has entered the cell, the viral cores and the encapsidated RC DNA are transported by host factors, via a nuclear localization signal, into the nucleus through the

ImpP/Impa nuclear transport receptors. Inside the nucleus, host DNA repair enzymes convert the RC DNA into cccDNA. cccDNA acts as the template for all viral mRNAs and as such, is responsible for HBV persistence in infected individuals. The transcripts produced from cccDNA are grouped into two categories; Pregenomic RNA (pgRNA) and subgenomic RNA. Subgenomic transcripts encode for the three envelopes (L, M and S) and X proteins, and pgRNA encodes for Pre-Core, Core, and Pol proteins (Quasdorff, M. & U. Protzer. J Viral Hepat, 17, (2010), 527- 36). Inhibition of HBV gene expression or HBV RNA synthesis leads to the inhibition of HBV viral replication and antigens production (Mao, R. et al. PLoS Pathog, 9, (2013), el 003494; Mao, R. et al. J Virol, 85, (2011), 1048-57). For instance, IFN-a was shown to inhibit HBV replication and viral HBsAg production by decreasing the transcription of pgRNA and subgenomic RNA from the HBV covalently closed circular DNA (cccDNA) minichromosome. (Belloni, L. et al. J Clin Invest, 122, (2012), 529-37; Mao, R. et al. J Virol, 85, (2011), 1048-57). All HBV viral mRNAs are capped and polyadenylated, and then exported to the cytoplasm for translation. In the cytoplasm, the assembly of new virons is initiated and nascent pgRNA is packaged with viral Pol so that reverse transcription of pgRNA, via a single stranded DNA intermediate, into RC DNA can commence. The mature nucleocapsids containing RC DNA are enveloped with cellular lipids and viral L, M, and S proteins and then the infectious HBV particles are then released by budding at the intracellular membrane (Locarnini, S. Semin Liver Dis, (2005), 25 Suppl 1, 9-19). Interestingly, non-infectious particles are also produced that greatly outnumber the infectious virions. These empty, enveloped particles (L, M and S) are referred to as subviral particles.

Importantly, since subviral particles share the same envelope proteins and as infectious particles, it has been surmised that they act as decoys to the host immune system and have been used for HBV vaccines. The S, M, and L envelope proteins are expressed from a single ORF that contains three different start codons. All three proteins share a 226aa sequence, the S-domain, at their C- termini. M and L have additional pre-S domains, Pre-S2 and Pre-S2 and Pre-Sl, respectively. However, it is the S -domain that has the HBsAg epitope (Lambert, C. & R. Prange. VirolJ, (2007), 4, 45).

The control of viral infection needs a tight surveillance of the host innate immune system which could respond within minutes to hours after infection to impact on the initial growth of the virus and limit the development of a chronic and persistent infection. Despite the available current treatments based on IFN and nucleos(t)ide analogues, the Hepatitis B virus (HBV) infection remains a major health problem worldwide which concerns an estimated 350 million chronic carriers who have a higher risk of liver cirrhosis and hepatocellular carcinoma.

The secretion of antiviral cytokines in response to HBV infection by the hepatocytes and/or the intra-hepatic immune cells plays a central role in the viral clearance of infected liver. However, chronically infected patients only display a weak immune response due to various escape strategies adopted by the virus to counteract the host cell recognition systems and the subsequent antiviral responses.

Many observations showed that several HBV viral proteins could counteract the initial host cellular response by interfering with the viral recognition signaling system and subsequently the interferon (IFN) antiviral activity. Among these, the excessive secretion of HBV empty subviral particles (SVPs, HBsAg) may participate to the maintenance of the immunological tolerant state observed in chronically infected patients (CHB). The persistent exposure to HBsAg and other viral antigens can lead to HBV-specific T-cell deletion or to progressive functional impairment (Nayersina et al. Journal of Immunology (1993), 150, 4659-4671; Kondo et al. Journal of

Medical Virology (2004), 74, 425-433; Fisicaro et al. Gastroenterology, (2010), 138, 682-93;). Moreover HBsAg has been reported to suppress the function of immune cells such as monocytes, dendritic cells (DCs) and natural killer (NK) cells by direct interaction (Op den Brouw et al. Immunology, (2009b), 126, 280-9; Woltman et al. PLoS One, (2011), 6, el5324; Shi et al. J Viral Hepat. (2012), 19, e26-33; Kondo et al. ISRN Gastroenterology, (2013), Article ID 935295).

HBsAg quantification is a significant biomarker for prognosis and treatment response in chronic hepatitis B. However the achievement of HBsAg loss and seroconversion is rarely observed in chronically infected patients but remains the ultimate goal of therapy. Current therapy such as Nucleos(t)ide analogues are molecules that inhibit HBV DNA synthesis but are not directed at reducing HBsAg level. Nucleos(t)ide analogs, even with prolonged therapy, have demonstrated rates of HBsAg clearance comparable to those observed naturally (between -1%- 2%) (Janssen et al. Lancet, (2005), 365, 123-9; Marcellin et al. N. Engl. J. Med., (2004), 351, 1206-17; Buster et al. Hepatology, (2007), 46, 388-94). Therefore, there is an unmet medical need to target HBsAg for HBV treatment (Wieland, S. F. & F. V. Chisari. J Virol, (2005), 79, 9369-80; Kumar et al. J Virol, (2011), 85, 987-95; Woltman et al. PLoS One, (2011), 6, el5324; Op den Brouw et al. Immunology, (2009b), 126, 280-9).

SUMMARY OF THE INVENTION

Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I as HBV inhibitors and for the treatment or prophylaxis of HBV infection. The compounds of formula I show superior anti-HBV activity.

The present invention relates to a compound of formula I,

wherein

R¹ is aminoCi_₆alkyl, Ci_₆alkyl, C3_₇cycloalkyl, carboxyCi_₆alkyl, cyanoCi_₆alkyl, haloCi_ 6alkyl, hydrogen or hydroxyCi_₆alkyl;

R² is phenyl, naphthyl, or heteroaryl, wherein said phenyl, naphthyl and heteroaryl is

unsubstituted or substituted with one, two or three substituents independently selected from 2-oxa-6-azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkoxy, Ci_₆alkyl, Ci_₆alkylamino, Ci_ 6alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, haloCi_₆alkyl, halogen, morpholinyl, nitro, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl; A is N or CH;

X is a bond or -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof. DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

As used herein, the term "Ci_₆alkyl" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert-butyl and the like. Particular "Ci_₆alkyl" groups are methyl, ethyl, isopropyl and tert-butyl. More particularly "Ci_₆alkyl" group is methyl.

The term "C3-₇cycloalkyl", alone or in combination, refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular "C₃_ ₇cycloalkyl" groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "Ci_₆alkoxy" alone or in combination signifies a group Ci_₆alkyl-0-, wherein the "Ci_₆alkyl" is as defined above; for example methoxy, ethoxy, propoxy, z^'so-propoxy, n-butoxy, z^'so-butoxy, 2-butoxy, tert-butoxy, pentoxy, hexyloxy and the like. Particular "Ci_₆alkoxy" groups are methoxy, ethoxy and propoxy. More particularly "Ci_₆alkoxy" group is methoxy. The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "haloCi_₆alkyl" denotes a Ci_₆alkyl group wherein at least one of the hydrogen atoms of the Ci_₆alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloCi_₆alkyl include monofluoro-, difluoro- or trifluoro-methyl, - ethyl or -propyl, for example 3,3,3-trifluoropropyl, 3,3- difluoropropyl, 2-fluoroethyl, 2,2- difluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoromethyl or trifluoromethyl. Particular "haloCi_₆alkyl" group is trifluoromethyl.

The term "amino" denotes a group of the formula -NR'R" wherein R' and R" are independently hydrogen or Ci_₆alkyl. Alternatively, R' and R", together with the nitrogen to which they are attached, can form a heteroC₃_₇cycloalkyl. The term "carbonyl" alone or in combination refers to the group -C(O)-.

The term "cyano" alone or in combination refers to the group -CN.

The term "Ci_₆alkylsulfonyl" denotes a group -S0₂-Ci_₆alkyl, wherein Ci_₆alkyl group is defined above. Examples of Ci_₆alkylsulfonyl include methylsulfonyl and ethylsulfonyl. The term "heteroaryl" denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples of heteroaryl moieties include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzo furanyl, isothiazolyl, benzothienyl, indolyl, indazolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl,

benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, imidazo[l,2-a]pyridinyl, pyrazolo[l,5-a]pyridinyl or quinoxalinyl. Particular "heteroaryl" groups are 1,2-benzoxazolyl, 1,3 -benzothiazolyl, benzimidazolyl, benzofuranyl, imidazo[l,2-a]pyridinyl, indazolyl, pyrazinyl, pyrazolo[l,5-a]pyridinyl, pyrazolyl, pyridinyl, thiazolyl and thienyl.

The term "halothienyl" denotes a thienyl substituted once, twice or three times by halogen. Examples of halothienyl include, but not limited to, bromothienyl, chlorothienyl, fluorothienyl, difluorothienyl and fluorochlorothienyl. Particular "halothienyl" groups are bromothienyl and chlorothienyl.

The term "enantiomer" denotes two stereoisomers of a compound which are non- superimposable mirror images of one another.

The term "diastereomer" denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities.

The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as /?-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435. Particular are the sodium salts of the compounds of formula I.

Compounds of the general formula I which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.

INHIBITOR OF HBsAg

The present invention provides (i) a compound having the general formula I:

wherein

R¹ is aminoCi_₆alkyl, Ci_₆alkyl, C3_₇cycloalkyl, carboxyCi_₆alkyl, cyanoCi_₆alkyl, haloCi_

₆alkyl, hydrogen or hydroxyCi_₆alkyl;

R² is phenyl, naphthyl, or heteroaryl, wherein said phenyl, naphthyl and heteroaryl are

unsubstituted or substituted with one, two or three substituents independently selected from 2-oxa-6-azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkoxy, Ci_₆alkyl, Ci_₆alkylamino, Ci_

₆alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, haloCi_₆alkyl, halogen, morpholinyl, nitro, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl; A is N or CH;

X is a bond or -C(=0)-; or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

A further embodiment of the present invention is (ii) a compound of formula I, wherein

R¹ is Ci_₆alkyl or hydrogen;

R² is phenyl, naphthyl or heteroaryl, wherein said phenyl and heteroaryl are unsubstituted or substituted with one, two or three substituents independently selected from 2-oxa-6- azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkoxy, Ci_₆alkyl, Ci_₆alkylamino, Ci_

6alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, haloCi_₆alkyl, halogen, morpholinyl, nitro, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl;

A is N or CH;

X is a bond or -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

Another embodiment of the present invention is (iii) a compound of formula I, wherein R¹ is Ci_₆alkyl;

R² is phenyl, naphthyl or heteroaryl, wherein said phenyl and heteroaryl are unsubstituted or substituted with one, two or three substituents independently selected from Ci_₆alkyl, Ci_ 6alkoxy, haloCi_6alkyl, halogen and nitro; said heteroaryl is 1 ,2-benzoxazolyl, 1,3- benzothiazolyl, benzimidazolyl, indazolyl, benzofuranyl, imidazo[l,2-a]pyridinyl, pyrazinyl, pyrazolo[l,5-a]pyridinyl, pyrazolyl, thiazolyl or thienyl;

A is N;

X is -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

Another embodiment of the present invention is (iv) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R¹ is methyl, and all remaining substituents have the significances given herein before.

Another embodiment of the present invention is (v) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is indazolyl, Ci_₆alkylindazolyl, Ci_₆alkoxythienyl, Ci_₆alkylthienyl or halothienyl, and all remaining substituents have the significances given herein before.

A further embodiment of the present invention is (vi) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is indazolyl, methylindazolyl, methoxythienyl, bromothienyl or chlorothienyl, and all remaining substituents have the significances given herein before.

Another embodiment of the present invention is (vii) a compound selected from

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-methylthiazol-2- yl)methanone;

(5-methoxy-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-[4- (trifluoromethyl)thiazol-2-yl]methanone;

(3-fluoro-5-methoxy-phenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- thienyl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(4-methyl-2- thienyl)methanone;

(4-bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-methyl-2- thienyl)methanone;

(5-chloro-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(4,5-dimethylthiazol-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone;

(l-methylpyrazol-4-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(l-methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(l-methylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

lH-benzimidazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone;

(4-methoxyphenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone; (l-ethylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim^ yl)methanone;

(5-bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydro^

thienyl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- naphthyl)methanone;

imidazo[l ,2-a]pyridin-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrol^

d]pyrimidin-6-yl)methanone;

(3-methylbenzofuran-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone;

(6-methoxypyrazin-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim 6-yl)methanone;

lH-indazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimid yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-pyra a]pyridin-3 -yl-methanone;

l ,3-benzothiazol-6-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim yl)methanone;

imidazo[l ,2-a]pyridin-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrol^

d]pyrimidin-6-yl)methanone;

1 ,2-benzoxazo 1-3 -yl-(5 -methyl-2-pyrimidin- yl)methanone; and

l ,3-benzothiazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimid yl)methanone;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

A further embodiment of the present invention is (viii) a compound which is (1- methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone; or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

Another embodiment of the present invention is (ix) a compound of formula I, wherein R¹ is Ci_₆alkyl or hydrogen; R² is phenyl substituted with one, two or three substituents independently selected from halogen and Ci_6alkoxy; or

pyridinyl substituted with one or two substituents independently selected from Ci_₆alkoxy, 2-oxa-6-azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkylamino, Ci_₆alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, halogen, morpholinyl, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl;

A is N or C;

X is a bond;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof. Another embodiment of the present invention is (x) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R¹ is methyl, and all remaining substituents have the significances given herein before.

Another embodiment of the present invention is (xi) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is pyridinyl substituted with one or two substituents independently selected from Ci_6alkoxy, azetidinyl, Ci_ ₆alkylamino, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, halogen, and oxopiperazinyl, and all remaining substituents have the significances given herein before.

A further embodiment of the present invention is (xii) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is pyridinyl substituted with one or two substituents independently selected from methoxy, azetidinyl, methylamino, methylsulfonylpiperazinyl, dimethylamino, fluoro and oxopiperazinyl, and all remaining substituents have the significances given herein before.

Another embodiment of the present invention is (xiii) a compound of formula I, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein A is N, and all remaining substituents have the significances given herein before.

Another embodiment of the present invention is (xiv) a compound selected from

6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine; 6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine;

6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin^ 6-(2,6-difluoro-4-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropy^

6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4- d]pyrimidine;

1- [4-[4-fluoro-6-(5-methyl-2-pyrimidin^

pyridyl]piperazin- 1 -yljethanone;

6-[6-fluoro-4-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim^

pyridyl] -2-oxa-6-azaspiro [3.3 ]heptane;

6-[2-fluoro-6-(5-methyl-2-pyrimi

pyridyl]-2-oxa-6-azaspiro[3.3]heptane;

2- fluoro-N-methyl-6-(5-methyl-2-pyrimidm^

yl)pyridin-4-amine;

2-fluoro-N,N-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3

6-yl)pyridin-4-amine;

6-[4-(azetidin-l-yl)-6-fluoro-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine;

6-(6-fluoro-4-pyrrolidin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine;

6-[6-fluoro-4-(l-piperidyl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7-dihydro^ d]pyrimidine;

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim^

pyridyl]morpholine;

6-(6-fluoro-4-piperazin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropy^ d]pyrimidine;

6- [6-fluoro-4-(4-methylsulfonylpiperazin- 1 -yl)-2-pyridyl] -5 -methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine; and

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim

pyridyl]piperazin-2-one;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

A further embodiment of the present invention is (xv) a compound selected from

6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine;

2-fluoro-N-methyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)pyridin-4-amine; 2-fluoro-N,N-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d^

6-yl)pyridin-4-amine;

6-[4-(azetidin-l-yl)-6-nuoro-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine;

6-[6-fluoro-4-(4-methylsulfonylpiperazin-l-yl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-^ dihydropyrrolo[3,4-d]pyrimidine; and

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidm^ pyridyl]piperazin-2-one;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof. SYNTHESIS

The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R¹, R², A and X are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.

General synthetic route for Compound la (Scheme 1)

Scheme 1

L is F, CI, Br, I

DMFDMA

The compound of formula la can be prepared according to Scheme 1.

Coupling of compound II with compound III, in the presence or absence of a catalyst such as Pd₂(dba)₃ or Pd(OAc)₂, a ligand such as Ruphos or BINAP and a base such as CS₂CO₃, K₂CO₃, or t-BuONa, in a suitable solvent such as 1 , 4-dioxane, DMSO or toluene, affords compound IV. Deprotection of compound IV under acidic condition affords compound V. Reaction of compound V with DMFDMA in the absence or presence of a suitable solvent such as DMF or acetonitrile generates intermediate VI. Compound la can be obtained by cyclization of intermediate VI with compound VII in the presence of a base such as K₂CO₃, NaOMe or Et₃N, in a suitable solvent such as EtOH or MeOH.

General synthetic route for Compound lb- A, Ib-B and Ib-C (Scheme 2)

Scheme 2

Ib-C

The compound of formula lb- A, Ib-B and Ib-C can be prepared according to Scheme 2, wherein L¹ is F, CI or Br; R³ and R⁴ are independently selected from hydrogen or Ci_₆alkyl; or R³ and R⁴ together with the nitrogen to which they are attached form 2-oxa-6- azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, morpholinyl, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl. Treatment of V-b with DMFDMA in the presence or absence of a suitable solvent such as DMF and CH₃CN produces intermediate Vl-b. Cyclization of Vl-b with compound VII affords compound Ib-1. The reaction can be carried out in the presence of a suitable base such as NaOMe, NaHC0₃ or K₂C0₃ in a suitable solvent such as MeOH or EtOH. Deprotection of compound Ib-1 with an acid such as HC1 or TFA generates intermediate Ib-2. Coupling of compound Ib-2 with halopyridine Ib-3 in the presence of a suitable base such as DIPEA in a suitable solvent such as DMSO or NMP gives compound Ib-4 and Ib-5. Compound lb- A, Ib-B and Ib-C can be obtained by reaction of compound Ib-4 or Ib-5 with amine NHPv³Pv⁴ in the presence of a suitable base such as K₂C0₃ or DIPEA in a suitable solvent such as NMP or DMSO, respectively.

General synthetic route for Compound Ic (Scheme 3)

Scheme 3

Ib-2 lc-1 Ic

The compound of formula Ic can be prepared according to Scheme 3. Coupling of Ib-2 with Ic-1 in the presence of a condensing agent such as HATU and a base such as DIPEA affords Ic.

This invention also relates to a process for the preparation of a compound of formula I comprising one of the following steps:

(a) cyclization of a compound of formula (A)

with a compound of formula (B)

in the presence of a base; (b) coupling of a compound of formula (C)

with a compound of formula (D)

NHR³R⁴ (D)

in the presence of a base; and

(c) coupling of a compound of formula (E)

with a compound of formula (F)

in the presence of a coupling reagent and a base;

wherein

R², A and X are defined as above;

L¹ is F, CI or Br;

One of W, Q and Y is N, the other two are CH;

R³ and R⁴ are independently selected from hydrogen or Ci_₆alkyl; or R³ and R⁴ together with the nitrogen to which they are attached form 2-oxa-6- azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkylcarbonylpiperazinyl, Ci_

6alkylsulfonylpiperazinyl, morpholinyl, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl,

In step (a), the base can be for example K₂C0₃, NaOMe or Et₃N;

In step (b), the base can be for example K₂C0₃ or DIEA;

In step (c), the coupling reagent can be for example HATU; the base can be for example DIPEA.

A compound of formula I when manufactured according to the above process is also an object of the invention.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

The invention also relates to a compound of formula I for use as therapeutically active substance.

Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit HBsAg. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.

In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.01 to 100 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 0.1 to about 1000 mg of the compound of the invention. The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

An example of a suitable oral dosage form is a tablet containing about 0.1 to 1000 mg of the compound of the invention compounded with about 0 to 2000 mg anhydrous lactose, about 0 to 2000 mg sodium croscarmellose, about 0 to 2000 mg polyvinylpyrrolidone (PVP) K30, and about 0 to 2000 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 0.1 to 1000 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.

An embodiment, therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

The following example A and B illustrate typical compositions of the present invention, but serve merely as representative thereof. Example A

A compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:

Per tablet

Active ingredient 200 mg

Microcrystalline cellulose 155 mg

Corn starch 25 mg

Talc 25 mg

Hydroxypropylmethylcellulose 20 mg

425 mg Example B

A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Per capsule Active ingredient 100.0 mg

Corn starch 20.0 mg

Lactose 95.0 mg

Talc 4.5 mg

Magnesium stearate 0.5 mg

220.0 mg

INDICATIONS AND METHODS OF TREATMENT

The compounds of the invention can inhibit HBsAg production or secretion and inhibit HBV gene expression. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.

The invention relates to the use of a compound of formula I for the inhibition of HBsAg production or secretion.

The invention relates to the use of a compound of formula I for the inhibition of HBV DNA production. The invention relates to the use of a compound of formula I for the inhibition of HBV gene expression.

The invention relates to the use of a compound of formula I for the treatment or prophylaxis of HBV infection.

The use of a compound of formula I for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HBV infection is an object of the invention.

The invention relates in particular to the use of a compound of formula I for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

Another embodiment includes a method for the treatment or prophylaxis of HBV infection, which method comprises administering an effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug, conjugates or pharmaceutically acceptable salt thereof.

EXAMPLES The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

Abbreviations used herein are as follows:

microliter

μιη: micrometer

μΜ: micromoles per liter

(Boc)₂0: di-tert-butyl dicarbonate

BSA: bovine serum albumin

IC₅₀: the half maximal inhibitory concentration

LC/MS: liquid chromatography/mass spectrometry

M: molarity

MHz: megahertz

hr(s): hour(s)

mM: millimoles per liter

MS (ESI): mass spectroscopy (electron spray ionization)

nM: nano moles per liter

NMR: nuclear magnetic resonance

obsd. observed

rt: room temperature

Pd/C: palladium on activated carbon

Pd₂(dba)₃: Tris(dibenzylideneacetone)dipalladium(0)

TFA: trifluoroacetic acid

δ: chemical shift

Xantphos 4 , 5 -Bis(dipheny lphosphino) -9 , 9-dimethy lxanthene

DMFDMA: N,N-dimethylformamide dimethyl acetal

tert-BuONa: sodium tert-butoxide

tert-BuOK: potassium tert-butoxide

DIPEA: N,N-diisopropylethylamine

TEA triethylamine

NMP: N-methyl-2-pyrrolidone

HATU N-[(Dimethylamino)- 1H- 1 ,2,3-triazolo-[4,5-b]pyridin- 1 -ylmethylene]-N- methylmethanaminium hexafluorophosphate N-oxide GENERAL EXPERIMENTAL CONDITIONS

Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module, ii) I SCO combi-flash chromatography instrument. Silica gel Brand and pore size: i) KP-S I L 60 A, particle size: 40-60 iim: ii) CAS registry NO: Silica Gel : 6323 1 -67-4, particle size: 47-60 micron silica gel : iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400. intermediates and final compounds were purified by preparative I I PLC on reversed phase column using X Bridge™ Perp Ci₈ (5 iim, OBD™ 30 100 mm) column or Sun Fire™ Perp Ci8 (5 μπι, OBD™ 30 100 mm) column. LC/MS spectra were obtained using an Acquity Ultra Performance LC - 3100 Mass

Detector or Acquity Ultra Performance LC - SQ Detector. Standard LC/MS conditions were as follows (running time 3 minutes):

Acidic condition: A: 0.1% formic acid in H₂0; B: 0.1% formic acid in acetonitrile;

Basic condition: A: 0.05% ΝΗ₃Ή₂0 in H₂0; B: acetonitrile;

Neutral condition : A : 1 LO; B: acetonitrile.

Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion ( M+H ) ^' .

The microwave assisted reactions were carried out in a Biotage Initiator Sixty or CEM Discover. NMR Spectra were obtained using Brukcr Avance 400 1 Iz.

All reactions involv ing air-sensitive reagents were performed under an argon atmosphere.

Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

PREPARATIVE EXAMPLES Example 1

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5- methylthiazol-2-yl)methanone

Step 1: Preparation of methyl 3-(benzylamino)butanoate

A mixture of methyl crotonate (20.0 g, 200.0 mmol), benzylamine (10.7 g, 100.0 mmol) in MeOH (500 mL) was stirred at rt for 72 hrs. The resulting reaction mixture was concentrated in vacuo to give crude methyl 3-(benzylamino)butanoate (20.3 g) as colorless oil, which was used in the next step without any further purification.

Step 2: Preparation of methyl 3-[benzyl-(2-ethoxy-2-oxo-ethyl)amino]butanoate

A mixture of methyl 3-(benzylamino)butanoate (20.3 g, 97.9 mmol), ethyl bromoacetate (19.3 g, 115.5 mmol) and K₂C0₃ (27.1 g, 195.8 mmol) in MeCN (275 mL) was stirred at rt for 15 hrs. The resulting reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by column (eluting with PE/EA=1 : 1, v:v) to give methyl 3-[benzyl-(2- ethoxy-2-oxo-ethyl)amino]-butanoate (20.5 g) as colorless oil. Step 3: Preparation of methyl l-benzyl-2-methyl-4-oxo-pyrrolidine-3-carboxylate

To a solution methyl 3-[benzyl-(2-ethoxy-2-oxo-ethyl)amino]-butanoate (20.5 g, 69.9 mmol) in toluene (500 mL) was added a solution of tert- uOK (9.4 g, 83.9 mmol) in THF (150 mL) slowly at 0°C under N₂ atmosphere. The resulting mixture was stirred at rt for 15 hrs. To the resulting mixture was added HC1 (1M, 135 mL, in H₂0). After being stirred at rt for 4 hrs, the resulting mixture was then neutralized with Na₂C03. The aqueous layer was separated and extracted with EA (100 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with PE/EA=3/l .v:v) to give methyl l-benzyl-2-methyl-4-oxo-pyrrolidine-3-carboxylate (10.0 g) as brown oil.

Step 4: Preparation of l-benzyl-5-methyl-pyrrolidin-3-one

A mixture of methyl l-benzyl-2-methyl-4-oxo-pyrrolidine-3-carboxylate (10.0 g, 40.44 mmol) and aqueous solution of H₂S0₄ (5%, prepared with 20.0 g con.H₂S0₄ and 380 mL water) was heated under reflux for 28 hrs. After being cooled to rt, the resulting mixture was neutralized with solid Na₂C03 and extracted with EA (100 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with PE/EA=10/1, v:v) to give l-benzyl-5-methyl-pyrrolidin-3-one (5.4 g) as yellow oil. Step 5: Preparation of tert-butyl 2-methyl-4-oxo-pyrrolidine-l-carboxylate

To a solution of l-benzyl-5-methyl-pyrrolidin-3-one (5.4 g, 28.5 mmol) and Boc₂0 (7.5 g, 34.4 mmol) in EtOH (50 mL) was added Pd/C (0.8 g, 10 wt%). The resulting mixture was stirred under H₂ (40 Psi) atmosphere at rt for 16 hrs and then filtered. The filtrate was concentrated in vacuo. The residue was purified by column (eluting with PE/EA= 20/1, v/v) to give tert-butyl 2- methyl-4-oxo-pyrrolidine-l-carboxylate (3.9 g) as colorless oil.

Step 6: Preparation of tert-butyl 5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidine-6-carboxylate

A mixture of tert-butyl 2-methyl-4-oxo-pyrrolidine-l-carboxylate (1.0 g, 5.0 mmol) and DMFDMA (10 mL) was heated at 120 °C with stirring 12 hrs under N₂. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (18 mL). To the solution was added pyrimidine-2-carboximidamide hydrochloride (1.45 g, 5.6 mmol) and K₂CO₃ (2.57 g, 18.6 mmol). The resulting mixture was heated at 60 °C with stirring for 2 hrs under N₂, was and then concentrated in vacuo. The residue was purified by prep-HPLC to give tert-butyl 5- methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (628 mg) as red oil.

Step 7: Preparation of 5-methyl-2-pyrimidin-2-yl-6,7-dihydro-5H-pyrrolo[3,4- d]pyrimidine hydrochloride

A mixture of tert-butyl 5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine-6- carboxylate (2.26 g, 7.21 mmol) and a solution of 1M HCl in EA (30 mL, 30 mmol) in MeOH (10 mL) was stirred at rt overnight. The resulting mixture was concentrated in vacuo to afford crude 5-methyl-2-pyrimidin-2-yl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (2.02 g) as a yellow solid, which was used in the next step without any further purification.

Step 8: Preparation of (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)-(5-methylthiazol-2-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (56.1 mg, 0.2 mmol), 5-methylthiazole-2-carboxylic acid (28.6 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified prep-HPLC to afford (5- methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-methylthiazol-2- yl)methanone (17 mg) as a yellow solid. 1H NMR (400MHz, CDC1₃) δ ppm: 9.00 (d, 2H), 8.92 - 8.82 (m, 1H), 7.60 - 7.53 (m, 1H), 7.42 (t, 1H), 6.70 - 5.73 (m, 1H), 5.70 - 4.93 (m, 2H), 2.52 - 2.45 (m, 3H), 1.68 - 1.55 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 339. Example 2

(5-Methoxy-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 5-methoxythiophene-2- carboxylic acid (31.6 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methoxy-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (17 mg) as a yellow solid. 1H NMR (400MHz, CDCls) δ ppm: 9.02 (d, 2H), 8.90 (s, 1H), 7.45 (t, 1H), 7.31 - 7.24 (m, 1H), 6.21 (d, 1H), 5.78 (m, 1H), 5.28 - 5.14 (m, 2H), 4.05 - 3.85 (m, 3H), 1.63 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 354.

Example 3

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-[4- (trifluoromethyl)-2-thienyl] methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 4- (trifluoromethyl)thiazole-2-carboxylic acid (39.4 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)-[4-(trifluoromethyl)-2-thienyl]methanone (16 mg) as a yellow solid. 1H NMR (400MHz, CDC1₃) δ ppm: 9.01 (d, 2H), 8.95 - 8.87 (m, 1H), 8.00 - 7.91 (m, 1H), 7.43 (t, 1H), 6.58 - 5.73 (m, 1H), 5.72 - 4.95 (m, 2H), 1.70 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 392.

Example 4 (3-Fluoro-5-methoxy-phenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

O

\

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 3-fluoro-5- methoxybenzoic acid (34 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (3-fluoro-5-methoxy-phenyl)-(5-methyl-2-pyrimidin-2-yl- 5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (19 mg) as a yellow solid. 1H NMR

(400MHz, CDC1₃) δ ppm: 9.06 - 8.80 (m, 3H), 7.43 - 7.33 (m, 1H), 6.87 - 6.75 (m, 2H), 6.68 (td, 1H), 5.81 - 5.28 (m, 1H), 5.04 - 4.69 (m, 2H), 3.78 (s, 3H), 1.56 - 1.75 (m, 2H). MS obsd. (ESI⁺) [(M+H)⁺]: 366.

Example 5 (5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- thienyl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), thiophene-2-carboxylic acid (25.6 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- thienyl)methanone (19 mg) as a yellow solid. 1H NMR (400MHz, CDC1₃) δ ppm: 8.99 (d, 2H), 8.89 (s, IH), 7.59 (dd, IH), 7.52 (dd, IH), 7.41 (t, IH), 7.10 (dd, IH), 5.79 (q, IH), 5.24 (s, 2H), 1.65 (br d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 324.

Example 6 (5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(4-methyl-2- thienyl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 4-methylthiophene-2- carboxylic acid (28.4 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)-(4-methyl-2-thienyl)methanone (15 mg) as a yellow solid. 1H NMR (400MHz, CDCls) δ ppm: 9.02 (d, 2H), 8.90 (s, 1H), 7.45 (t, 1H), 7.43 - 7.26 (m, 1H), 7.11 (s, 1H), 5.83 - 5.72 (m, 1H), 5.30 - 5.16 (m, 2H), 2.28 - 2.16 (m, 3H), 1.68 - 1.59 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 338.

Example 7

(4-Bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 4-bromothiophene-2- carboxylic acid (41.4 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (4-bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (22 mg) as a yellow solid. 1H NMR (400MHz, CDCI3) δ ppm: 9.00 (d, 2H), 8.90 (s, 1H), 7.46 (d, 1H), 7.45 - 7.41 (m, 2H), 5.77 (q, 1H), 5.22 (d, 2H), 1.65 (br d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 402.

Example 8

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-methyl-2- thienyl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 5-methylthiophene-2- carboxylic acid (28.4 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)-(5-methyl-2-thienyl)methanone (15 mg) as a yellow solid. 1H NMR (400MHz, CDCI3) δ ppm: 9.01 (d, 2H), 8.89 (s, 1H), 7.43 (t, 1H), 7.39 (d, 1H), 6.76 (dd, 1H), 5.78 (q, 1H), 5.27 - 5.15 (m, 2H), 2.48 (s, 3H), 1.63 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 338.

Example 9

(5-Chloro-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 56.1 mg, 0.2 mmol), 5-chlorothiophene-2- carboxylic acid (32.5 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-chloro-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (11 mg) as a yellow solid. 1H NMR (400MHz, CDCls) δ ppm: 9.00 (d, 2H), 8.89 (s, 1H), 7.43 (t, 1H), 7.34 (d, 1H), 6.93 (d, 1H), 5.76 (q, 1H), 5.25 - 5.13 (m, 2H), 1.64 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 358.

Example 10 (4,5-Dimethylthiazol-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 4,5-dimethylthiazole-2- carboxylic acid (15.7 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (4,5-dimethylthiazol-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (14 mg) as a yellow solid. 1H NMR (400MHz, CDCI3) δ ppm: 9.10 - 8.76 (m, 3H), 7.49 - 7.34 (m, 1H), 6.65 - 5.70 (m, 1H), 5.70 - 4.90 (m, 2H), 2.41 - 2.28 (m, 6H), 1.72 - 1.63 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 353.

Example 11

(l-Methylpyrazol-4-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 1 -methyl- lH-pyrazole- 4-carboxylic acid (12.6 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 1 hr. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (l-methylpyrazol-4-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (12 mg) as a yellow solid. 1H NMR (400MHz, CDCls) δ ppm: 9.08 (br d, 2H), 8.97 (s, 1H), 7.95 (s, 1H), 7.90 (s, 1H), 7.51 (t, 1H), 5.90 - 5.75 (m, 1H), 5.24 (br s, 2H), 4.00 (s, 3H), 1.77 - 1.72 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 322.

Example 12

(l-Methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 1 -methyl- lH-indazole- 3-carboxylic acid (17.6 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 1 hr. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (l-methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (13mg) as a yellow solid. 1H NMR (400MHz, CDCI3) δ ppm: 9.08 - 8.84 (m, 3H), 8.36 (d, 1H), 7.46 - 7.36 (m, 3H), 7.30 - 7.22 (m, 1H), 6.66 - 5.80 (m, 1H), 5.70 - 5.01 (m, 2H), 4.17 - 4.03 (m, 3H), 1.73 - 1.50 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 372.

Example 13

(l-Methylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 1 -methyl- lH-pyrazole- 3-carboxylic acid (12.6 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (l-methylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (13 mg) as a yellow solid. 1H NMR (400MHz, CDCI3) δ ppm: 9.20 - 8.95 (m, 3H), 7.60 - 7.53 (m, 1H), 7.51 - 7.41 (m, 1H), 6.95 - 6.90 (m, 1H), 6.60 - 5.80 (m, 1H), 5.73 - 5.03 (m, 2H), 4.05 - 3.94 (m, 3H), 1.82 - 1.71 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 322.

Example 14 lH-Benzimidazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), H-benzo[d]imidazole-2- carboxylic acid (16.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford lH-benzimidazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (17 mg) as a yellow solid. 1H NMR (400MHz,

DMSO- 6) δ ppm: 13.35 - 13.26 (m, 1H), 9.16 - 9.06 (m, 1H), 9.03 (d, 2H), 7.89 - 7.27 (m, 5 ), 6.81 - 5.73 (m, 1H), 5.72 - 4.95 (m, 2H), 1.74 - 1.59 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 358.

Example 15

(4-Methoxyphenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)methanone

O—

To a mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1 , 28.1 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DCM (1 mL) was added 4-methoxybenzoyl chloride (17.1 mg, 0.1 mmol) at 0 °C. The resulting mixture was warmed to rt and stirred for 20 hrs, then diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- HPLC to afford (4-methoxyphenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (14 mg) as a yellow solid. 1H NMR (400MHz, CDC1₃) δ ppm: 9.08 (d, 2H), 8.94 (br s, 1H), 7.60 (br d, 2H), 7.52 (t, 1H), 6.97 (d, 2H), 5.86 (br s, 1H), 5.20 - 5.09 (m, 1H), 4.94 (br s, 1H), 3.88 (s, 3H), 1.70 (br s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 348.

Example 16

(l-Ethylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 1 -ethyl- lH-pyrazole-3- carboxylic acid (14 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (l-ethylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (17 mg) as a yellow solid. 1H NMR (400MHz, CDC1₃) δ ppm: 9.07 (d, 2H), 8.98 - 8.90 (m, 1H), 7.52 - 7.41 (m, 2H), 6.95 - 6.88 (m, 1H), 6.55 - 5.78 (m, 1H), 5.70 - 4.99 (m, 2H), 4.32 - 4.12 (m, 2H), 1.74 (d, 3H), 1.56 (t, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 336. Example 17

(5-Bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 5-bromothiophene-2- carboxylic acid (20.7 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (10 mg) as an off-white solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.08 - 8.97 (m, 3H), 7.71 - 7.61 (m, 2H), 7.38 (d, 1H), 5.72 - 5.57 (m, 1H), 5.41 (br d, 1H), 5.18 (br d, 1H), 1.59 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 402.

Example 18

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-nitro-2- thienyl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 5-nitrothiophene-2- carboxylic acid (17.3 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5- nitro-2-thienyl)methanone (11 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.11 - 8.96 (m, 3H), 8.19 (d, 1H), 7.87 (d, 1H), 7.66 (t, 1H), 6.05 - 5.60 (m, 1H), 5.55 - 4.95 (m, 2H), 1.72 - 1.40 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 369. Example 19

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- naphthyl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 2-naphthoic acid (17.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(2- naphthyl)methanone (7 mg) as an off-white solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.14 - 8.91 (m, 3H), 8.37 - 7.97 (m, 4H), 7.80 - 7.57 (m, 4H), 5.81 - 5.57 (m, 1H), 5.41 - 4.65 (m, 2H), 1.82 - 1.18 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 368.

Example 20 Imidazo [ 1 ,2-a] pyridin-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyr rolo [3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), imidazo[l,2-a]pyridine- 2-carboxylic acid (16.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford imidazo[l,2-a]pyridin-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (9 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.17 - 8.95 (m, 3H), 8.67 - 8.48 (m, 2H), 7.77 - 7.29 (m, 3H), 7.08 - 6.66 (m, 1H), 5.74 - 4.91 (m, 3H), 1.71 - 1.47 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 358.

Example 21

(3-Methylbenzofuran-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 3-methylbenzofuran-2- carboxylic acid (17.6 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (3-methylbenzofuran-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (8 mg) as an off-white solid. 1H NMR

(400MHz, DMSO- 6) δ ppm: 9.25 - 8.83 (m, 3H), 7.94 - 7.26 (m, 5 ), 6.25 - 5.63 (m, 1H), 5.60 - 4.90 (m, 2H), 2.51 (s, 3H), 1.73 - 1.38 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 372.

Example 22

(6-Methoxypyrazin-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), 6-methoxypyrazine-2- carboxylic acid (15.4 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (6-methoxypyrazin-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (7 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.04 - 8.91 (m, 3H), 8.67 - 8.55 (m, 1H), 8.51 - 8.41 (m, 1H), 7.64 - 7.56 (m, 1H), 6.15 - 5.62 (m, 1H), 5.47 - 4.89 (m, 2H), 4.01 - 3.96 (m, 3H), 1.63 - 1.28 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 350.

Example 23 lH-indazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), lH-indazole-3- carboxylic acid (16.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford lH-indazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (5 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 13.72 (br s, 1H), 9.04 - 8.91 (m, 3H), 8.22 - 8.11 (m, 1H), 7.67 - 7.54 (m, 2H), 7.44 - 7.34 (m, 1H), 7.21 (t, 1H), 6.43 - 5.64 (m, 1H), 5.49 - 4.87 (m, 2H), 1.64 - 1.43 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 358.

Example 24

(5-Methyl-2-pyrimidin-2-yl-5,7-dihydropy rrolo [3,4-d] pyrimidin-6-yl)-pyrazolo [ 1 ,5- a]pyridin-3-yl-methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), pyrazolo[l,5-a]pyridine- 3-carboxylic acid (16.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)-pyrazolo[l,5-a]pyridin-3-yl-methanone (10 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.06 - 8.90 (m, 3H), 8.84 - 8.72 (m, 1H), 8.60 (s, 1H), 8.21 (d, 1H), 7.60 (t, 1H), 7.46 (ddd, 1H), 7.07 (dt, 1H), 5.70 (br s, 1H), 5.53 - 4.97 (m, 2H), 1.55 (br d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 358.

Example 25 l,3-Benzothiazol-6-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), benzo[d]thiazole-6- carboxylic acid (17.9 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford l,3-benzothiazol-6-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (10 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.54 (s, 1H), 9.10 - 8.91 (m, 3H), 8.54 (br s, 1H), 8.19 (br d, 1H), 7.87 - 7.59 (m, 2H), 5.80 - 5.50 (m, 1H), 5.36 - 4.66 (m, 2H), 1.75 - 1.10 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 375.

Example 26

Imidazo [ 1 ,2-a] pyridin-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyr rolo [3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), imidazo[l,2-a]pyridine- 3-carboxylic acid (16.2 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford imidazo[l,2-a]pyridin-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (10 mg) as a pink solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.42 (br d, 1H), 9.13 - 8.97 (m, 3H), 8.63 (s, 1H), 7.88 (d, 1H), 7.76 - 7.62 (m, 2H), 7.31 (t, 1H), 5.90 - 5.78 (m, 1H), 5.55 - 5.16 (m, 2H), 1.65 (br d, 3H). MS obsd. (ESI⁺)

[(M+H)⁺]: 358.

Example 27 l,2-Benzoxazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), benzo[d]isoxazole-3- carboxylic acid (16.3 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and TEA (30.4 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford l,2-benzoxazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone (6 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.16 - 8.94 (m, 3H), 8.10 - 8.00 (m, 1H), 7.88 - 7.78 (m, 1H), 7.68 (t, 1H), 7.55 (dd, 1H), 7.33 (dd, 1H), 6.32 - 5.72 (m, 1H), 5.64 - 5.01 (m, 2H), 1.76 - 1.50 (m, 3H). MS obsd. (ESI⁺)

[(M+H)⁺]: 359.

Example 28 l,3-Benzothiazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidin-6-yl)methanone

A mixture of 5-methyl-2-(pyrimidin-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (the product of step 7 in Example 1, 28.1 mg, 0.1 mmol), benzo[d]thiazole-2- carboxylic acid (17.9 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIPEA (38.8 mg, 0.3 mmol) in DMF (1 mL) was stirred at rt for 64 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford l,3-benzothiazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidin-6-yl)methanone (6 mg) as a yellow solid. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.17 - 8.97 (m, 3H), 8.25 (d, 2H), 7.73 - 7.56 (m, 3H), 6.62 - 5.70 (m, 1H), 5.68 - 4.99 (m, 2H), 1.74 - 1.63 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 375. Example 29

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine \

Step 1: Preparation of benzyl l,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate

A mixture of benzyl 3-oxopyrrolidine-l-carboxylate (20 g, 91.3 mmol), paraforaldehyde (17 g, 0.274 mol) and toluenesulfonic acid monohydrate (867 mg, 4.57 mmol) in toluene (200 mL) was heated under reflux with Dean-Stark apparatus for 36 hrs. After being cooled to rt, the resulting mixture was washed with saturated aqueous NaHC0₃ solution (200 mL) and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with PE/EA=5/1, v:v) to give benzyl l,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate (15 g) as a colorless oil.

Step 2: Preparation of l,4-dioxa-7-azaspiro[4.4]nonane

A solution of benzyl l,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate (8 g, 30.4 mmol) in MeOH (80 mL) was stirred in the presence of Pd/C (0.5 g, lOwt. %) under H₂ (30 Psi) at rt for 12 hrs. The mixture was filtered and the filtrate was concentrated in vacuo to give l,4-dioxa-7- azaspiro[4.4]nonane (3 g) as a colorless oil, which was used in the next step without any further purification.

Step 3: Preparation of 7-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-7- azaspiro [4.4] nonane

A mixture of l,4-dioxa-7-azaspiro[4.4]nonane (2 g, 15.5 mmol), 5-bromo-l,2-difluoro-3- methoxy-benzene (4.47 g, 20.1 mmol), tert-BuONa (2.23 g, 23.25 mmol), Xantphos (325 mg) and Pd₂(dba)₃ (258 mg) in dioxane (20 mL) was heated at 100 °C with stirring under N₂ for 16 firs. The resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with DCM (200 mL), then washed with water and brine, dried over Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with PE/EA=5/1, v:v) to give 7-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-7-azaspiro[4.4]nonane (2.7 g) as a yellow oil Step 4: Preparation of l-(3,4-difluoro-5-methoxy-phenyl)pyrrolidin-3-one

A mixture of 7-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-7-azaspiro[4.4]nonane (1 g, 3.7 mmol), formic acid (5 mL) and H₂0 (5 mL) was heated at 90 °C with stirring for 2 hrs. After being cooled to rt, the resulting mixture was diluted with DCM, then washed with water, saturated aqueous NaHC0₃ and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with PE/EA=5/1, v:v) to give l-(3,4-difluoro-5- methoxy-phenyl)pyrrolidin-3-one (350 mg) as a yellow solid.

Step 5: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-5,7- dihydropyrrolo[3,4-d]pyrimidine \

A mixture of l-(3,4-difluoro-5-methoxy-phenyl)pyrrolidin-3-one (350 mg, 1.54 mmol) and DMFDMA (5 mL) was heated at 120 °C with stirring for 4 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in MeOH (5 mL). To the solution was added pyridine-2-carboximidamide hydrochloride (246 mg, 1.56 mmol) and K₂CO₃ (474 mg, 3.43 mmol). The resulting mixture was heated at 60 °C with stirring for 16 hrs. After being cooled to rt, the resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with DCM (50 mL), then washed with brine, dried over anhydrous Na₂S0₄ and

concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(3,4-difluoro-5- methoxy-phenyl)-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine (10 mg) as a white solid. 'HNMR (400MHZ, DMSO- 6) δ ppm: 3.93 (s, 3 H), 4.73 (d, 4 H), 6.24 - 6.37 (m, 2 H), 7.49 - 7.60 (m, 1 H), 8.00 (t, 1 H), 8.39 (d, 1 H), 8.76 (d, 1 H), 8.98 (s, 1 H). MS obsd. (ESI⁺) [(M+H)⁺]: 341.

Example 30 6-(6-Fluoro-4-methoxy-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo [3,4- d]pyrimidine

Step 1: Preparation of 5-methyl-2-pyrimidin-2-yl-6,7-dihydro-5H-pyrrolo[3,4- d]pyrimidine

A mixture of tert-butyl 5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine-6- carboxylate (628.0 mg, 2.0 mmol) and a solution of HC1 in EA (20 mL, 4M) was stirred at rt for 15 hrs under N₂. The resulting reaction mixture was concentrated in vacuo and the residue was diluted with MeOH (20 mL). The resulting solution was neutralized with basic resin and filtered. The filtrate was concentrated in vacuo to give crude 5-methyl-2-pyrimidin-2-yl-6,7-dihydro-5H- pyrrolo[3,4-d]pyrimidine (436.0 mg) as red solid, which was used in the next step without any further purification.

Step 2: Preparation of 6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-pyrimidin-2-yl- 5,7-dihydropyrrolo[3,4-d]pyrimidine

A mixture of 5-methyl-2-pyrimidin-2-yl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine (400.0 mg, 1.8 mmol), 2,6-difluoro-4-methoxypyridine (406.0 mg, 2.8 mmol) and DIPEA (696.0 mg, 5.4 mmol) in NMP (12 mL) was heated at 120 °C with stirring for 5 hrs. The resulting reaction mixture was poured into saturated aqueous NaHC0₃ (20 mL) and extracted with DCM (20 mL) for three times. The combined organic phase was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(6-fluoro- 4-methoxy-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine (62.3 mg) as white solid. 1H NMR (400 MHz, CDC1₃) δ ppm: 9.06 (s, 2 H), 8.91 (s, 1 H), 7.48 - 7.46 (t, 1 H), 5.88 (s, 1 H), 5.81 (s, 1 H), 5.58 - 5.56 (m, 1 H), 4.93 - 4.80 (m, 2 H), 3.88 (s, 3 H), 1.70 - 1.68 (d, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 339. Example 31 and 32

6-(4,6-Difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d] pyrimidine and 6-(2,6-difluoro-4-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine

Example 31 Example32

A mixture of 2,4,6-trifluoropyridine (1.9 g, 14.07 mmol), 5-methyl-2-pyrimidin-2-yl-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine (1.5 g, 7.03 mmol) and DIPEA (3.68 mL, 21.1 mmol) in NMP (15 mL) was heated at 150 °C with stirring in a microwave reactor for 1 hr. The resulting reaction mixture was diluted with H₂0 (100 mL) and extracted with EA (100 mL) for three times. The combined organic layer was dried over anhydrous MgSC^ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2- yl-5,7-dihydropyrrolo[3,4-d]pyrimidine (400 mg) as light yellow solid and 6-(2,6-difluoro-4- pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine (640 mg) as light yellow solid.

Example 31 : 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine, 1H NMR (400 MHz, CDC1₃) δ ppm: 9.06 (d, 2 H), 8.93 (s, 1 H), 7.48 (t, 1 H), 7.28 (s, 1 H), 6.05 (d, 2 H), 5.57 (dd, 1 H), 5.31 (s, 1 H), 4.80 - 4.94 (m, 2 H), 1.70 (d, 3 H). MS obsd. (ESI+) [(M+H)⁺]: 327.

Example 32: 6-(2,6-difluoro-4-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine, 1H NMR (400 MHz, CDC1₃) δ ppm: 9.07 (d, 2 H), 8.97 (s, 1 H), 7.50 (t, 1 H), 7.28 (s, 1 H), 6.08 (s, 2 H), 5.35 (dd, 1 H), 4.93 (dd, 1 H), 4.80 (d, 1 H), 1.67 (d, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 327.

Example 33

Stepl: Preparation of tert-buty\ 5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4- d]pyrimidine-6-carboxylate

A mixture of tert-butyl 2-methyl-4-oxo-pyrrolidine-l-carboxylate (3.0 g, 15.0 mmol) and DMFDMA (30 mL) was heated at 120 °C with stirring for 12 hrs under N₂. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (40 mL). To the solution was added pyridine-2-carboximidamide hydrochloride (2.4 g, 15.0 mmol) and

K₂CO₃ (6.2 g, 45.0 mmol). The mixture was heated at 60 °C with stirring for 2 hrs under N₂. The resulting reaction mixture was concentrated in vacuo and the residue was purified prep-HPLC to give tert-butyl 5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (1.2 g) as red oil. Step 2: Preparation of 5-methyl-2-(2-pyridyl)-6,7-dihydro-5H-pyrrolo[3,4- d]pyrimidine

A mixture of tert-butyl 5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6- carboxylate (800 mg, 2.6 mmol) and a solution of HC1 in EA (10 mL, 2M) was stirred at rt for 15 hrs under N₂. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (10 mL). he resulting mixture was stirred with basic resin for 4 hrs at rt and then filtered. The filtrate was concentrated in vacuo to give 5-methyl-2-(2-pyridyl)-6,7-dihydro- 5H-pyrrolo[3,4-d]pyrimidine (400 mg, crude) as brown oil, which was used in the next step without any further purification.

Step 3: Preparation of 6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-(2-pyridyl)-5,7- dihydropyrrolo [3,4-d] pyrimidine

A mixture of 5-methyl-2-(2-pyridyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine (200 mg, 0.8 mmol), 2,6-difluoro-4-methoxypyridine (175 mg, 1.2 mmol) and DIPEA (310 mg, 2.4 mmol) in NMP (5 mL) was heated at 120 °C with stirring for 15 hrs. The resulting mixture was poured into aqueous saturated NaHC0₃ (20 mL) and extracted with DCM (30 mL) for three times. The combined organic phases were washed with brine (20 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(6-fluoro-4-methoxy-2- pyridyl)-5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine (5 mg) as light yellow solid. 1H NMR (400 MHz, CDC1₃) δ ppm: 9.00 - 9.14 (m, 1 H), 8.89 (s, 1 H), 8.82 (d, 1 H), 8.32 (br t, 1 H), 7.82 (br t, 1 H), 5.84 - 5.92 (m, 2 H), 5.52 - 5.59 (m, 1 H), 4.78 - 4.92 (m, 2 H), 3.90 (s, 3 H), 3.14 (br d, 1 H), 1.70 (d, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 338.

Example 34 l-[4-[4-Fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)-2-pyridyl] piperazin- 1-yl] ethanone F

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), l-(piperazin-l-yl)ethanone (76.9 mg, 0.6 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMSO (2 mL) was heated at 120 °C with stirring for 20 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The crude was purified by prep-HPLC to afford l-[4-[4- fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2-pyridyl]- piperazin-l-yl]ethanone (5 mg) as a yellow powder. 1H NMR (400MHz, DMSO-<¾) δ ppm: 9.13 - 8.97 (m, 3H), 7.66 (t, 1H), 6.03 (dd, 1H), 5.93 - 5.81 (dd, 1H), 5.50 (br d, 1H), 4.89 - 4.66 (m, 2H), 3.64 - 3.48 (m, 8H), 2.05 (s, 3H), 1.62 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 435.

Example 35

6-[6-Fluoro-4-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl] -2-oxa-6-azaspiro [3.3 ] heptane

A mixture of 6-(2,6-difiuoro-4-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 32, 131 mg, 0.4 mmol), 2-oxa-6-azaspiro[3.3]heptane hemioxalate (173 mg, 0.6 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMSO (2 mL) was heated at 130 °C with stirring for 20 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-[6-fluoro-4-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl]-2-oxa-6-azaspiro[3.3]heptane (9 mg) as a yellow powder. 1H NMR (400MHz, DMSO- d₆) δ ppm: 9.10 - 8.97 (m, 3H), 7.67 (t, 1H), 5.80 (s, 1H), 5.51 - 5.35 (m, 2H), 4.89 - 4.65 (m, 6H), 4.15 - 4.04 (m, 4H), 1.52 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 406.

Example 36 6-[4-Fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl] -2-oxa-6-azaspiro [3.3 ] heptane

A mixture of 6-(4,6-difiuoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), 2-oxa-6-azaspiro[3.3]heptane hemioxalate (173 mg, 0.6 mmol) and DIPEA (77.5 mg, 0.6 mmol) in DMSO (2 mL) was heated at 130 °C with stirring for 20 hrs. The resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The crude was purified by prep-HPLC to afford 6-[4-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl]-2-oxa-6-azaspiro[3.3]heptane (3 mg) as a yellow powder. 1H NMR (400MHz, DMSO- d₆) δ ppm: 9.10 - 8.95 (m, 3H), 7.66 (t, 1H), 5.49 - 5.36 (m, 3H), 4.85 - 4.64 (m, 6H), 4.12 (m, 4H), 1.57 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 406.

Example 37

2-Fluoro- V-methyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)pyridin-4-amine

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 97.9 mg, 0.3 mmol), methanamine hydrochloride (101 mg, 1.5 mmol) and DIPEA (233 mg, 1.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 2-fluoro-N-methyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)pyridin-4-amine (48 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.04 - 8.98 (m, 3H), 7.66 (t, 1H), 6.66 (br d, 1H), 5.56 (s, 1H), 5.44 - 5.34 (m, 1H), 4.83 - 4.65 (m, 2H), 3.76 - 3.66 (m, 1H), 2.75 (d, 3H), 1.58 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 338.

Example 38

2-Fluoro- V V-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)pyridin-4-amine

A mixture of 6-(4,6-difiuoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 97.9 mg, 0.3 mmol), dimethylamine hydrochloride (122 mg, 1.5 mmol) and DIPEA (233 mg, 1.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep- HPLC to afford 2-fiuoro-N,N-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)pyridin-4-amine (45 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- d6) δ ppm: 9.10 - 8.95 (m, 3H), 7.66 (t, 1H), 5.72 (s, 1H), 5.59 (s, 1H), 5.50 - 5.40 (m, 1H), 4.87 - 4.69 (m, 2H), 3.00 (s, 6H), 1.59 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 352.

Example 39

6-[4-(Azetidin-l-yl)-6-fluoro-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), azetidine hydrochloride (56.1 mg, 0.6 mmol) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 6-[4-(azetidin-l-yl)-6-fluoro-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine (22 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- d6) δ ppm: 9.05 - 8.98 (m, 3H), 7.66 (t, 1H), 5.46 - 5.33 (m, 3H), 4.84 - 4.67 (m, 2H), 3.94 (t, 4H), 2.35 (quin, 2H), 1.58 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 364. Example 40

6-(6-Fluoro-4-pyrrolidin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), pyrrolidine (42.7 mg, 0.6 mmol) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 6-(6- fluoro-4-pyrrolidin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (21 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 8.99 - 8.90 (m, 3H), 7.59 (t, 1H), 5.50 (s, 1H), 5.44 - 5.33 (m, 2H), 4.79 - 4.62 (m, 2H), 3.25 - 3.21 (m, 4H), 1.96 - 1.84 (m, 4H), 1.52 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 378.

Example 41 6-[6-Fluoro-4-(l-piperidyl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine

A mixture of 6-(4,6-difiuoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), piperidine (51.1 mg, 0.6 mmol) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 6-[6- fluoro-4-(l-piperidyl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (35 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 8.99 - 8.90 (m, 3H), 7.59 (t, 1H), 5.83 (s, 1H), 5.73 (s, 1H), 5.43 - 5.34 (m, 1H), 4.79 - 4.61 (m, 2H), 3.35 - 3.29 (m, 4H), 1.60 - 1.45 (m, 9H). MS obsd. (ESI⁺) [(M+H)⁺]: 392.

Example 42

4-[2-Fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl] morpholine

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), morpholine (52.3 mg, 0.6 mmol) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 4-[2- fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl]morpholine (28 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 8.99 - 8.92 (m, 3H), 7.59 (t, 1H), 5.89 (s, 1H), 5.79 (s, 1H), 5.44 - 5.34 (m, 1H), 4.81 - 4.64 (m, 2H), 3.68 - 3.61 (m, 4H), 3.26 - 3.23 (m, 4H), 1.51 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 394. Example 43

6-(6-Fluoro-4-piperazin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine

A mixture of 6-(4,6-difiuoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), piperazine (51.7 mg, 0.6 mmol,) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 110 °C for lhr in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 6-(6- fluoro-4-piperazin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (43 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 8.98 - 8.92 (m, 3H), 7.59 (t, 1H), 5.84 (s, 1H), 5.74 (s, 1H), 5.43 - 5.34 (m, 1H), 4.80 - 4.61 (m, 2H), 3.21 - 3.17 (m, 4H), 2.77 - 2.68 (m, 4H), 1.51 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 393.

Example 44 6-[6-Fluoro-4-(4-methylsulfonylpiperazin-l-yl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl- 5,7-dihydropyrrolo[3,4-d]pyrimidine =o

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), l-(methylsulfonyl)piperazine (98.5 mg, 0.6 mmol) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 130 °C for 3 hrs in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep- HPLC to afford 6-[6-fluoro-4-(4-methylsulfonylpiperazin-l-yl)-2-pyridyl]-5-methyl-2- pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidine (23 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 8.98 - 8.90 (m, 3H), 7.59 (t, 1H), 5.93 (s, 1H), 5.83 (s, 1H), 5.45 - 5.34 (m, 1H), 4.82 - 4.63 (m, 2H), 3.51 - 3.40 (m, 4H), 3.19 - 3.09 (m, 4H), 2.86 (s, 3H), 1.51 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 471.

Example 45

4-[2-Fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl] piperazin-2-one

A mixture of 6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidine (Example 31, 65.3 mg, 0.2 mmol), piperazin-2-one (60.1 mg, 0.6 mmol,) and DIPEA (233 mg, 0.8 mmol) in DMSO (1 mL) was heated at 130 °C for 3 hrs in a microwave reactor. After being cooled to rt, the resulting reaction mixture was purified by prep-HPLC to afford 4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl]piperazin-2-one (13 mg) as a light yellow powder. 1H NMR (400MHz, DMSO- 6) δ ppm: 9.05 - 8.97 (m, 3H), 8.20 (br s, 1H), 7.66 (t, 1H), 5.93 (s, 1H), 5.80 (s, 1H), 5.48 (br d, 1H), 4.89 - 4.72 (m, 2H), 3.93 (s, 2H), 3.56 (br t, 2H), 3.35 - 3.27 (m, 2H), 1.59 (d, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 407.

BIOLOGICAL EXAMPLES

Example 46 materials and methods

HBV cell line

HepG2.2.15 cells (Acs et al. Proc Natl Acad Sci USA, 84, (1987), 4641-4), a

constitutively HBV-expressing cell line were cultured in DMEM+Glutamax-I medium

(Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen) and G418 (Invitrogen) at a final concentration of 200 mg/L and maintained in 5% C0₂ at 37°C.

HBsAg Assay

HepG2.2.15 cells were seeded in duplicate into white, 96-well plates at 1.5 x 10⁴ cells/well. The cells were treated with a three-fold serial dilution series of the compounds in DMSO. The final DMSO concentration in all wells was 1% and DMSO was used as no drug control.

The HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2) was used to measure the levels of secreted HBV antigens semi-quantitatively. For the detection 50 μΙ,ΛνεΙΙ culture supernatant was used and HBsAg was quantified using HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2), 50 μΐ, of the supernatant was transferred to the CLIA assay plate and 50 μΐ_^ of enzyme conjugate reagent was added into each well. The plates were sealed and gently agitated for 1 hour at room temperature. The

supernatant-enzyme-mixture was discarded and wells were washed 6 times with 300 μΐ, of PBS. The residual liquid was removed by plating the CLIA plate right side down on absorbent tissue paper. 25 μΐ, of substrates A and B were added to each well. Luminance was measured using a luminometer (Mithras LB 940 Multimode Microplate Reader) after 10 minutes incubation. Dose- response curves were generated and the IC₅₀ value was extrapolated by using the E-WorkBook Suite (ID Business Solutions Ltd., Guildford, UK). The IC₅₀ was defined as the compound concentration (or conditioned media log dilution) at which HBsAg secretion was reduced by 50% compared to the no drug control.

The compounds according to formula I were tested for their capacity to inhibit HBsAg as described herein. The Examples were tested in the above assay and found to have IC₅₀ below 50 μΜ. Particular compounds of formula I were found to have IC₅₀ below 0.50 μΜ. More Particular compounds of formula I were found to have ICso below 0.100 μΜ. Results of HBsAg assay are given in Table 1.

Table 1 : Activity data in HBsAg assay

Example ICso Example Example Example ICso

ICso (μΜ) ICso (μΜ)

No. (μΜ) No. No. No. (μΜ)

12 0.158 24 0.156 36 0.865

HBV DNA assay

The assay employs real-time qPCR (TaqMan ) to directly measure extracellular HBV DNA copy number in the cell supernatant. HepG2.2.15 ceils were plated in 96 -well microtiter plates before treatment with com lete medium (DM EM. Glutamax. 10% I BS, 1%

Pen i c i 11 i n/S t repto myc i n . 250 μ^ mL Genetycin. final DM SO concentration is 1%). Only the interior wells were utilized to reduce "edge effects" observed during cel l culture, the exterior wells were filled with complete medium to help minimize sample evaporation. The HepG2.2.15 cells were treated lh later with various concentrations of a test compound in duplicate (top concentration used at 5 μ Μ, 2 μ Μ or 0.5 μΜ according to the 1 1 BsAg IC50 observed, with 1/3 successive dilutions (total of 1 0 dilutions). Si days following the initial administration of the test compound, the cell culture supernatant was collected; DNA extraction was performed by automated system (Magnapure) and then used in a real-time qPCR TaqMan assay to determine HBV DNA copy numbers. Antiviral activity was calculated from the reduction in HBV DNA levels (ICso). The compounds of the present invention were tested for their capacity to inhibit HBV

DNA as described herein. The Examples were tested in the above assay and found to have ICso below 50 μΜ. Particular compounds of formula I were found to have ICso below 500 nM. More Particular compounds of formula I were found to have ICso below 100 nM. Results of HBV DNA assay are given in Table 2.

Table 2: Anti HBV DNA production activity in HepG2.2.15 cells

Example No. ICso (nM)

10 67.6

12 5.6

21 26.2

30 6.5

Claims

A compound of formula I,

wherein

unsubstituted or substituted with one, two or three substituents independently selected from 2-oxa-6-azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkoxy, Ci_₆alkyl, Ci_₆alkylamino, Ci_ 6alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, haloCi_₆alkyl, halogen, morpholinyl, nitro, oxopiperazmyl, piperazinyl, piperidinyl and pyrrolidinyl;

A is N or CH;

X is a bond or -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

2. A compound according to claim 1, wherein

R¹ is Ci_₆alkyl or hydrogen;

6alkylcarbonylpiperazinyl, Ci_₆alkylsulfonylpiperazinyl, diCi_₆alkylamino, haloCi_₆alkyl, halogen, morpholinyl, nitro, oxopiperazmyl, piperazinyl, piperidinyl and pyrrolidinyl; A is N or CH;

X is a bond or -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

3. A compound according to claim 1, wherein

R¹ is Ci_₆alkyl;

R² is phenyl, naphthyl or heteroaryl, wherein said phenyl and heteroaryl are unsubstituted or substituted with one, two or three substituents independently selected from Ci_₆alkyl, Ci_

6alkoxy, haloCi_6alkyl, halogen and nitro; said heteroaryl is 1 ,2-benzoxazolyl, 1,3- benzothiazolyl, benzimidazolyl, indazolyl, benzofuranyl, imidazo[l,2-a]pyridinyl, pyrazinyl, pyrazolo[l,5-a]pyridinyl, pyrazolyl, thiazolyl or thienyl;

A is N;

X is -C(=0)-;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

4. A compound according to any one of claims 1, 2 or 3, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R¹ is methyl.

5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is indazolyl, Ci_6alkylindazolyl, Ci_

6alkoxythienyl, Ci_₆alkylthienyl or halothienyl.

6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is indazolyl, methylindazolyl,

methoxythienyl, bromothienyl or chlorothienyl.

7. A compound according to claim 1, selected from

(3-fluoro-5-methoxy-phenyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone; (5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin^

thienyl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(4-meth thienyl)methanone;

(4-bromo-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-(5-meth thienyl)methanone;

(5-chloro-2-thienyl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimid yl)methanone;

(4,5-dimethylthiazol-2-yl)-(5-methy^

d]pyrimidin-6-yl)methanone;

(l-methylpyrazol-4-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidm yl)methanone;

(l-methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrm yl)methanone;

(l-methylpyrazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidm yl)methanone;

lH-benzimidazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimid yl)methanone;

(4-methoxyphenyl)-(5-methyl-2-pyrimidm^

yl)methanone;

( 1 -ethylpyrazo 1-3 -yl)-(5 -methyl-2-pyrimM

yl)methanone;

(5-bromo-2-thienyl)-(5-methyl-2-pyrim

yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-di^^

thienyl)methanone;

imidazo[l,2-a]pyridin-2-yl-(5-methyL

d]pyrimidin-6-yl)methanone; (3-methylbenzofuran-2-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- d]pyrimidin-6-yl)methanone;

lH-indazol-3-yl-(5-methyl-2-pyrimidin^

yl)methanone;

(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-pyraz

a]pyridin-3 -yl-methanone;

l,3-benzothiazol-6-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim yl)methanone;

imidazo[l,2-a]pyridin-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo

d]pyrimidin-6-yl)methanone;

1.2- benzoxazol-3-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- yl)methanone; and

1.3- benzothiazol-2-yl-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim yl)methanone;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

8. A compound according to claim 1, which is

(l-methylindazol-3-yl)-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)methanone; or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

9. A compound according to claim 1, wherein

R¹ is Ci_₆alkyl or hydrogen;

R² is phenyl substituted with one, two or three substituents independently selected from

halogen and Ci_6alkoxy; or

A is N or C;

X is a bond;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

10. A compound according to any one of claims 1, 2 or 9, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R¹ is methyl.

11. A compound according to any one of claims 1, 2, 9 or 10, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is pyridinyl substituted with one or two substituents independently selected from Ci_6alkoxy, azetidinyl, Ci_6alkylamino, Ci_

6alkylsulfonylpiperazinyl, diCi_₆alkylamino, halogen, and oxopiperazinyl.

12. A compound according to any one of claims 1, 2, 9, 10, 11 or 12, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein R² is pyridinyl substituted with one or two substituents independently selected from methoxy, azetidinyl, methylamino, methylsulfonylpiperazinyl, dimethylamino, fluoro and oxopiperazinyl.

13. A compound according to any one of claims 1, 2, 9, 10, 1 1 or 12, or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof, wherein A is N.

14. A compound according to claim 1, selected from

6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine;

6-(4,6-difluoro-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidm^ 6-(2,6-difluoro-4-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidm^ 6-(6-fluoro-4-methoxy-2-pyridyl)-5-methyl-2-(2-pyridyl)-5,7-dihydropyrrolo[3,4- d]pyrimidine;

l-[4-[4-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl]piperazin- 1 -yljethanone;

6-[6-fluoro-4-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-2- pyridyl] -2-oxa-6-azaspiro [3.3 ]heptane;

6-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl] -2-oxa-6-azaspiro [3.3 ]heptane; 2-fluoro-N-methyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4- yl)pyridin-4-amine;

2-fluoro-N,N-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo

6-yl)pyridin-4-amine;

6-[6-fluoro-4-(l-piperidyl)-2-pyridyl]-5-mem^

d]pyrimidine;

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim^

pyridyl]morpholine;

6-(6-fluoro-4-piperazin-l-yl-2-pyridyl)-5-methyl-2-pyrimidin-2-yl-5,7-dihydro^ d]pyrimidine;

6-[6-fluoro-4-(4-methylsulfonylpiperazin-l-yl)-2-pyridyl]-5-methyl-2-pyrimi

dihydropyrrolo[3,4-d]pyrimidine; and

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrim

pyridyl]piperazin-2-one;

or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

15. A compound according to claim 1, selected from

2-fluoro-N-methyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6- yl)pyridin-4-amine;

2-fluoro-N,N-dimethyl-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin- 6-yl)pyridin-4-amine;

6-[6-fluoro-4-(4-methylsulfonylpiperazin-l-yl)-2-pyridyl]-5-methyl-2-pyrimidin-2-yl-5,7- dihydropyrrolo[3,4-d]pyrimidine; and

4-[2-fluoro-6-(5-methyl-2-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)-4- pyridyl]piperazin-2-one; a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.

16. A process for the preparation of a compound according to any one of claims 1 to 15 comprising one of the following steps:

(a) cyclization of a compound of formula (A)

with a compound of formula (B)

in the presence of a base;

(b) coupling of a compound of formula (C)

with a compound of formula (D)

NHR³R⁴ (D)

in the presence of a base; (c) coupling of a compound of formula (E)

(E) with a compound of formula (F)

in the presence of a coupling reagent and a base; wherein,

R², A and X are defined as in any one of claims 1 to 15;

L¹ is F, CI or Br;

One of W, Q and Y is N, the other two are CH;

R³ and R⁴ are independently selected from hydrogen or Ci_₆alkyl; or

R³ and R⁴ together with the nitrogen to which they are attached form 2-oxa-6- azaspiro[3.3]heptanyl, azetidinyl, Ci_₆alkylcarbonylpiperazinyl, Ci_

₆alkylsulfonylpiperazinyl, morpholinyl, oxopiperazinyl, piperazinyl, piperidinyl and pyrrolidinyl.

17. A compound according to any one of claims 1 to 15 for use as therapeutically active substance.

18. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 15 and a therapeutically inert carrier.

19. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of HBV infection.

20. The use of a compound according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

21. The use of a compound according to any one of claims 1 to 15 for the inhibition of HBsAg production or secretion, or for the inhibition of HBV DNA production.

22. A compound according to any one of claims 1 to 15 for the treatment or prophylaxis of HBV infection.

23. A compound according to any one of claims 1 to 15, when manufactured according to a process of claim 16.

24. A method for the treatment or prophylaxis of HBV infection, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 15.

25. The invention as hereinbefore described.